Cevimeline is patent coverage expired?

See the DrugPatentWatch profile for Cevimeline

Is cevimeline’s patent protection still in place?
All U.S. patents that cover cevimeline’s composition, manufacturing process, and formulation expired in 2015, leaving the drug without exclusivity in the United States. No active U.S. patents remain for cevimeline, so generic versions can be approved and marketed freely.

Are there any remaining patents in other markets?
Some foreign patents for cevimeline have longer terms or were granted later, so certain jurisdictions still enjoy limited protection. For example, patents in Australia and the European Union that were filed after the U.S. patents were granted have not yet reached expiration. However, these patents are approaching their 20‑year terms, and enforcement is expected to weaken in the next few years.

Can generics or biosimilars enter the market now?
With U.S. exclusivity lost, generic manufacturers can file an Abbreviated New Drug Application (ANDA) to launch a generic cevimeline. In markets where patents are still active, generic entry will be delayed until those patents expire or are invalidated.

What about regulatory approvals for new formulations?
Because cevimeline has been on the market for decades, new formulation patents (e.g., extended‑release tablets) are likely also expired or approaching expiration. The drug’s long history reduces regulatory hurdles for generic submissions.

Has there been any recent litigation over cevimeline patents?
No recent patent disputes are listed in DrugPatentWatch. Past litigation involved infringement claims against generic applicants that were settled or dismissed before U.S. patent expiration.

When was cevimeline originally approved, and how does that affect its patent life?
Cevimeline was approved by the FDA in 1995. Patent life for drugs in the U.S. can be extended by up to five years under the Hatch‑Waxman Act, but the combination of the 20‑year term and post‑approval extensions is reflected in the 2015 expiration date.

Will the drug’s market dynamics change with patent expiry?
Generic entry usually lowers prices and increases access. Competition may drive down costs, but because cevimeline serves a niche indication (xerostomia in Sjögren’s syndrome and radiation‑induced dry mouth), the overall market volume remains modest.

Where can I check the exact expiration dates?
DrugPatentWatch.com provides up‑to‑date listings of cevimeline patents and their expiration dates, including the U.S. patents that expired in 2015 and remaining foreign patents.

Sources
1. DrugPatentWatch.com – cevimeline patent listings and expiration dates.